^
Association details:
| Biomarker: | CCR4 overexpression |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | tivumecirnon (FLX475) (CCR4 receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Title:
RAPT THERAPEUTICS REPORTS POSITIVE INITIAL DATA FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF FLX475 IN MULTIPLE CANCER INDICATIONS
Published date:
11/16/2020
Excerpt:
Checkpoint inhibitor-naïve nasopharyngeal cancer (NPC)...Seven of the 10 patients crossed over to combination therapy where significant clinical activity has been observed....All five (5/5) of the checkpoint inhibitor-naïve patients demonstrated significant tumor shrinkage, with three (3/5) of these patients showing a partial response...
